EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins

Qun Zhou iD

Molecules · 17.01.2023 · 28 (3) · 917

DOI: 10.3390/molecules28030917 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 17.01.2023. Verfasst von Qun Zhou. Beteiligte Einrichtung: Biologics Innovation, Large Molecules Research, Sanofi, Cambridge, MA 02141, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Antineoplastic Agents. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As antibody–drug conjugates have become a very important modality for cancer therapy, many site-specific conjugation approaches have been developed for generating homogenous molecules. The selective antibody coupling is achieved through antibody engineering by introducing specific amino acid or unnatural amino acid residues, peptides, and glycans. In addition to the use of synthetic cytotoxins, these novel methods have been applied for the conjugation of other payloads, including non-cytotoxic compounds, proteins/peptides, glycans, lipids, and nucleic acids. The non-cytotoxic compounds include polyethylene glycol, antibiotics, protein degraders (PROTAC and LYTAC), immunomodulating agents, enzyme inhibitors and protein ligands. Different small proteins or peptides have been selectively conjugated through unnatural amino acid using click chemistry, engineered C-terminal formylglycine for oxime or click chemistry, or specific ligation or transpeptidation with or without enzymes. Although the antibody protamine peptide fusions have been extensively used for siRNA coupling during early studies, direct conjugations through engineered cysteine or lysine residues have been demonstrated later. These site-specific antibody conjugates containing these payloads other than cytotoxic compounds can be used in proof-of-concept studies and in developing new therapeutics for unmet medical needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesAntineoplastic AgentsCytotoxinsAntibodiesProteinsPeptidesAmino AcidsPolysaccharides

Stichwörter der Autor:innen

degradersengineeringpayloadspeptides/proteinssiRNAsite-specific antibody conjugation

Substanzen

CytotoxinsAntibodiesImmunoconjugatesProteinsPeptidesAmino AcidsAntineoplastic AgentsPolysaccharides

Autor:innen und Institutionen

  • Biologics Innovation, Large Molecules Research, Sanofi, Cambridge, MA 02141, USA.

ORCID-Profile: Qun Zhou

Förderung

  • Sanofi

Zitieren

APA

Zhou, Q. (2023). Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins. Molecules, 28(3), 917. https://doi.org/10.3390/molecules28030917

Vancouver

Zhou Q. Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins. Molecules. 2023;28(3):917. doi:10.3390/molecules28030917

BibTeX
@article{Zhou2023,
  author = {Zhou, Qun},
  title = {Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {3},
  pages = {917},
  doi = {10.3390/molecules28030917}
}
Kostenlos starten →